Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression
Open accessThe DOI matches its Crossref record; 38 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The global surge in the omicron (B.1.1.529) variant has resulted in many individuals with hybrid immunity (immunity developed through a combination of SARS-CoV-2 infection and vaccination). We aimed to systematically review the magnitude and duration of the protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against infection and severe disease caused by the omicron variant. METHODS: For this systematic review and meta-regression, we searched for cohort, cross-sectional, and case-control studies in MEDLINE, Embase, Web of Science, ClinicalTrials.gov, the Cochrane Central Register of Controlled Trials, the WHO COVID-19 database, and Europe PubMed Central from Jan 1, 2020, to June 1, 2022, using keywords related to SARS-CoV-2, reinfection, protective effectiveness, previous infection, presence of antibodies, and hybrid immunity. The main outcomes were the protective effectiveness against reinfection and against hospital admission or severe disease of hybrid immunity, hybrid immunity relative to previous infection alone, hybrid immunity relative to previous vaccination alone, and hybrid immunity relative to hybrid immunity with fewer vaccine doses. Risk of bias was assessed with the Risk of Bias In Non-Randomized Studies of Interventions Tool. We used log-odds random-effects meta-regression to estimate the magnitude of protection at 1-month intervals. This study was registered with PROSPERO (CRD42022318605). FINDINGS: 11 studies reporting the protective effectiveness of previous SARS-CoV-2 infection and 15 studies reporting the protective effectiveness of hybrid immunity were included. For previous infection, there were 97 estimates (27 with a moderate risk of bias and 70 with a serious risk of bias). The effectiveness of previous infection against hospital admission or severe disease was 74·6% (95% CI 63·1-83·5) at 12 months. The effectiveness of previous infection against reinfection waned to 24·7% (95% CI 16·4-35·5) at 12 months. For hybrid immunity, there were 153 estimates (78 with a moderate risk of bias and 75 with a serious risk of bias). The effectiveness of hybrid immunity against hospital admission or severe disease was 97·4% (95% CI 91·4-99·2) at 12 months with primary series vaccination and 95·3% (81·9-98·9) at 6 months with the first booster vaccination after the most recent infection or vaccination. Against reinfection, the effectiveness of hybrid immunity following primary series vaccination waned to 41·8% (95% CI 31·5-52·8) at 12 months, while the effectiveness of hybrid immunity following first booster vaccination waned to 46·5% (36·0-57·3) at 6 months. INTERPRETATION: All estimates of protection waned within months against reinfection but remained high and sustained for hospital admission or severe disease. Individuals with hybrid immunity had the highest magnitude and durability of protection, and as a result might be able to extend the period before booster vaccinations are needed compared to individuals who have never been infected. FUNDING: WHO COVID-19 Solidarity Response Fund and the Coalition for Epidemic Preparedness Innovations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, given the known variability in dual human data extraction accuracy (reported rates: 65.8-85.5%) 14-19 , original author-extracted values were not treated as a definitive gold standard”
From Automation of Systematic Reviews with Large Language Models (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“For human data extraction, we determined sample size using a McNemar test for sample size approximation. Using an estimated human accuracy of 80% (reported rates: 65.8-85.5%) 14-19 , LLM accuracy of 90%, and 95% confidence, we determined a minimum number of 204 variables per study to be extracted.”
From Automation of Systematic Reviews with Large Language Models (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Prior research has shown wide variability in the accuracy of dual human extraction, with reported rates ranging from 65.8-85.5% 14-19 .”
From Automation of Systematic Reviews with Large Language Models (2025) · cites this paper as [15]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003583 · Cited by 5,148
COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates
Sallam, M. (2021) · Vaccines · doi:10.3390/vaccines9020160 · Cited by 2,128
Feikin, D. R., Higdon, M. M., Abu-Raddad, L. J., Andrews, N., Araos, R., Goldberg, Y., Groome, M. J., Huppert, A., O'Brien, K. L., Smith, P. G., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00152-0 · Cited by 1,237
Self-citationNyberg, T., Ferguson, N. M., Nash, S. G., Webster, H. H., Flaxman, S., Andrews, N., Hinsley, W., Bernal, J. L., Kall, M., Bhatt, S., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00462-7 · Cited by 1,221
Nyberg, T., Ferguson, N. M., Nash, S., Webster, H. H., Flaxman, S. R., Andrews, N. J., Hinsley, W. R., Bernal, J. L., Kall, M. M., Bhatt, S., et al. (2022) · Northumbria Research Link (Northumbria University) · doi:10.17863/cam.81883 · Cited by 1,129
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
Altarawneh, H. N., Chemaitelly, H., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Coyle, P., Al-Kanaani, Z., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203965 · Cited by 551
Self-citationLong-term neurologic outcomes of COVID-19
Xu, E., Xie, Y., & Al-Aly, Z. (2022) · Nature Medicine · doi:10.1038/s41591-022-02001-z · Cited by 530
Notarte, K. I., Catahay, J. A., Velasco, J. V., Pastrana, A., Ver, A. T., Pangilinan, F. C., Peligro, P. J., Casimiro, M., Guerrero, J. J., Gellaco, M. M. L., et al. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101624 · Cited by 480
Cited by
Link‐Gelles, R., Ciesla, A. A., Mak, J., Miller, J. D., Silk, B. J., Lambrou, A. S., Paden, C. R., Shirk, P., Britton, A., Smith, Z., et al. (2024) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7304a2 · Cited by 156
Meslé, M. M. I., Brown, J., Mook, P., Katz, M. A., Hagan, J., Pastore, R., Benka, B., Redlberger‐Fritz, M., Bossuyt, N., Stouten, V., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00179-6 · Cited by 153
Link‐Gelles, R., Ciesla, A. A., Roper, L. E., Scobie, H. M., Ali, A. R., Miller, J. D., Wiegand, R. E., Accorsi, E. K., Verani, J. R., Shang, N., et al. (2023) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7205e1 · Cited by 140
Relan, P., Motaze, N. V., Kothari, K. U., Askie, L. M., de Waroux, O. L. P., Kerkhove, M. D. V., Diaz, J. V., & Vijayaraghavan, B. K. T. (2023) · BMJ Global Health · doi:10.1136/bmjgh-2023-012328 · Cited by 138
Jones, J. M., Manrique, I. M., Stone, M., Grebe, E., Saá, P., Germanio, C. D., Spencer, B. R., Notari, E. P., Bravo, M. D., Lanteri, M. C., et al. (2023) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7222a3 · Cited by 137
Metadata
- Authors
- Bobrovitz, N., Ware, H., Ma, X., Li, Z., Hosseini, R., Cao, C., Selemon, A., Whelan, M., Premji, Z., Issa, H., Cheng, B., Abu Raddad, L. J., Buckeridge, D. L., Van Kerkhove, M. D., Piechotta, V., Higdon, M. M., Wilder-Smith, A., Bergeri, I., Feikin, D. R., Arora, R. K., Patel, M. K., & Subissi, L.
- Affiliations
- University of Calgary (CA)
- University of Toronto (CA)
- University of British Columbia (CA)
- University of Victoria (CA)
- University College London (GB)
- McGill University (CA)
- Robert Koch Institute (DE)
- Johns Hopkins University (US)
- World Health Organization (CH)
- Corresponding author
- Bobrovitz, Niklas
- ORCID
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2023-05
- Volume
- 23
- Issue
- 5
- Pages
- 556-567
- ISSN
- 1473-3099 (ISSN-L)
- PMC
- PMC10014083
- OpenAlex
- W4317356311
- Cited by
- 614
- References
- 41
- Citations by year
- 2026: 68 · 2025: 131 · 2024: 227 · 2023: 187
- FWCI
- 29.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet Infectious Diseases (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Publication server of the Robert Koch Institute (Robert Kock Institute) (acceptedVersion, cc-by)
- Publication server of the Robert Koch Institute (Robert Kock Institute) (submittedVersion, cc-by)
- UVic’s Research and Learning Repository (University of Victoria) (submittedVersion)
- Funders
- World Health Organization
- Coalition for Epidemic Preparedness Innovations
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- SARS-CoV-2, Omicron variant, hybrid immunity, prior SARS-CoV-2 infection, reinfection, protective effectiveness, severe COVID-19, hospitalization, waning immunity, COVID-19 vaccination, antibody response, duration of protection, risk of bias, risk of bias in non-randomized studies
- MeSH terms
- Reinfection, COVID-19, SARS-CoV-2, Cross-Sectional Studies, Humans, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. https://app.cochat.ai/papers/10.1016/s1473-3099(22)00801-5
- The paper
- Bobrovitz, N., Ware, H., Ma, X., Li, Z., Hosseini, R., Cao, C., Selemon, A., Whelan, M., Premji, Z., Issa, H., Cheng, B., Abu Raddad, L. J., Buckeridge, D. L., Van Kerkhove, M. D., Piechotta, V., Higdon, M. M., Wilder-Smith, A., Bergeri, I., Feikin, D. R., . . . Subissi, L. (2023). Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(22)00801-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.